Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Research
Open Access

Booster vaccination with inactivated whole-virus or mRNA vaccines and COVID-19–related deaths among people with multimorbidity: a cohort study

Francisco Tsz Tsun Lai, Vincent Ka Chun Yan, Xuxiao Ye, Tiantian Ma, Xiwen Qin, Celine Sze Ling Chui, Xue Li, Eric Yuk Fai Wan, Carlos King Ho Wong, Ching Lung Cheung, Philip Hei Li, Bernard Man Yung Cheung, Chak Sing Lau, Ian Chi Kei Wong and Esther Wai Yin Chan
CMAJ January 30, 2023 195 (4) E143-E152; DOI: https://doi.org/10.1503/cmaj.221068
Francisco Tsz Tsun Lai
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy (Lai, Yan, Ye, Ma, Qin, X. Li, Wan, C.K.H. Wong, C.L. Cheung, I.C.K. Wong, Chan), Li Ka Shing Faculty of Medicine, The University of Hong Kong; Laboratory of Data Discovery for Health (Lai, Ma, Chui, X. Li, Wan, C.K.H. Wong, C.L. Cheung, I.C.K. Wong, Chan), Hong Kong Science and Technology Park; School of Nursing (Chui) and of Public Health (Chui) and Departments of Medicine (X. Li, P.H. Li, B.M.U. Cheung, Lau) and of Family Medicine and Primary Care, School of Clinical Medicine (Wan, C.K.H. Wong), Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; Aston Pharmacy School (I.C.K. Wong), Aston University, Birmingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent Ka Chun Yan
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy (Lai, Yan, Ye, Ma, Qin, X. Li, Wan, C.K.H. Wong, C.L. Cheung, I.C.K. Wong, Chan), Li Ka Shing Faculty of Medicine, The University of Hong Kong; Laboratory of Data Discovery for Health (Lai, Ma, Chui, X. Li, Wan, C.K.H. Wong, C.L. Cheung, I.C.K. Wong, Chan), Hong Kong Science and Technology Park; School of Nursing (Chui) and of Public Health (Chui) and Departments of Medicine (X. Li, P.H. Li, B.M.U. Cheung, Lau) and of Family Medicine and Primary Care, School of Clinical Medicine (Wan, C.K.H. Wong), Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; Aston Pharmacy School (I.C.K. Wong), Aston University, Birmingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xuxiao Ye
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy (Lai, Yan, Ye, Ma, Qin, X. Li, Wan, C.K.H. Wong, C.L. Cheung, I.C.K. Wong, Chan), Li Ka Shing Faculty of Medicine, The University of Hong Kong; Laboratory of Data Discovery for Health (Lai, Ma, Chui, X. Li, Wan, C.K.H. Wong, C.L. Cheung, I.C.K. Wong, Chan), Hong Kong Science and Technology Park; School of Nursing (Chui) and of Public Health (Chui) and Departments of Medicine (X. Li, P.H. Li, B.M.U. Cheung, Lau) and of Family Medicine and Primary Care, School of Clinical Medicine (Wan, C.K.H. Wong), Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; Aston Pharmacy School (I.C.K. Wong), Aston University, Birmingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tiantian Ma
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy (Lai, Yan, Ye, Ma, Qin, X. Li, Wan, C.K.H. Wong, C.L. Cheung, I.C.K. Wong, Chan), Li Ka Shing Faculty of Medicine, The University of Hong Kong; Laboratory of Data Discovery for Health (Lai, Ma, Chui, X. Li, Wan, C.K.H. Wong, C.L. Cheung, I.C.K. Wong, Chan), Hong Kong Science and Technology Park; School of Nursing (Chui) and of Public Health (Chui) and Departments of Medicine (X. Li, P.H. Li, B.M.U. Cheung, Lau) and of Family Medicine and Primary Care, School of Clinical Medicine (Wan, C.K.H. Wong), Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; Aston Pharmacy School (I.C.K. Wong), Aston University, Birmingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiwen Qin
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy (Lai, Yan, Ye, Ma, Qin, X. Li, Wan, C.K.H. Wong, C.L. Cheung, I.C.K. Wong, Chan), Li Ka Shing Faculty of Medicine, The University of Hong Kong; Laboratory of Data Discovery for Health (Lai, Ma, Chui, X. Li, Wan, C.K.H. Wong, C.L. Cheung, I.C.K. Wong, Chan), Hong Kong Science and Technology Park; School of Nursing (Chui) and of Public Health (Chui) and Departments of Medicine (X. Li, P.H. Li, B.M.U. Cheung, Lau) and of Family Medicine and Primary Care, School of Clinical Medicine (Wan, C.K.H. Wong), Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; Aston Pharmacy School (I.C.K. Wong), Aston University, Birmingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Celine Sze Ling Chui
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy (Lai, Yan, Ye, Ma, Qin, X. Li, Wan, C.K.H. Wong, C.L. Cheung, I.C.K. Wong, Chan), Li Ka Shing Faculty of Medicine, The University of Hong Kong; Laboratory of Data Discovery for Health (Lai, Ma, Chui, X. Li, Wan, C.K.H. Wong, C.L. Cheung, I.C.K. Wong, Chan), Hong Kong Science and Technology Park; School of Nursing (Chui) and of Public Health (Chui) and Departments of Medicine (X. Li, P.H. Li, B.M.U. Cheung, Lau) and of Family Medicine and Primary Care, School of Clinical Medicine (Wan, C.K.H. Wong), Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; Aston Pharmacy School (I.C.K. Wong), Aston University, Birmingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xue Li
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy (Lai, Yan, Ye, Ma, Qin, X. Li, Wan, C.K.H. Wong, C.L. Cheung, I.C.K. Wong, Chan), Li Ka Shing Faculty of Medicine, The University of Hong Kong; Laboratory of Data Discovery for Health (Lai, Ma, Chui, X. Li, Wan, C.K.H. Wong, C.L. Cheung, I.C.K. Wong, Chan), Hong Kong Science and Technology Park; School of Nursing (Chui) and of Public Health (Chui) and Departments of Medicine (X. Li, P.H. Li, B.M.U. Cheung, Lau) and of Family Medicine and Primary Care, School of Clinical Medicine (Wan, C.K.H. Wong), Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; Aston Pharmacy School (I.C.K. Wong), Aston University, Birmingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Yuk Fai Wan
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy (Lai, Yan, Ye, Ma, Qin, X. Li, Wan, C.K.H. Wong, C.L. Cheung, I.C.K. Wong, Chan), Li Ka Shing Faculty of Medicine, The University of Hong Kong; Laboratory of Data Discovery for Health (Lai, Ma, Chui, X. Li, Wan, C.K.H. Wong, C.L. Cheung, I.C.K. Wong, Chan), Hong Kong Science and Technology Park; School of Nursing (Chui) and of Public Health (Chui) and Departments of Medicine (X. Li, P.H. Li, B.M.U. Cheung, Lau) and of Family Medicine and Primary Care, School of Clinical Medicine (Wan, C.K.H. Wong), Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; Aston Pharmacy School (I.C.K. Wong), Aston University, Birmingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos King Ho Wong
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy (Lai, Yan, Ye, Ma, Qin, X. Li, Wan, C.K.H. Wong, C.L. Cheung, I.C.K. Wong, Chan), Li Ka Shing Faculty of Medicine, The University of Hong Kong; Laboratory of Data Discovery for Health (Lai, Ma, Chui, X. Li, Wan, C.K.H. Wong, C.L. Cheung, I.C.K. Wong, Chan), Hong Kong Science and Technology Park; School of Nursing (Chui) and of Public Health (Chui) and Departments of Medicine (X. Li, P.H. Li, B.M.U. Cheung, Lau) and of Family Medicine and Primary Care, School of Clinical Medicine (Wan, C.K.H. Wong), Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; Aston Pharmacy School (I.C.K. Wong), Aston University, Birmingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ching Lung Cheung
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy (Lai, Yan, Ye, Ma, Qin, X. Li, Wan, C.K.H. Wong, C.L. Cheung, I.C.K. Wong, Chan), Li Ka Shing Faculty of Medicine, The University of Hong Kong; Laboratory of Data Discovery for Health (Lai, Ma, Chui, X. Li, Wan, C.K.H. Wong, C.L. Cheung, I.C.K. Wong, Chan), Hong Kong Science and Technology Park; School of Nursing (Chui) and of Public Health (Chui) and Departments of Medicine (X. Li, P.H. Li, B.M.U. Cheung, Lau) and of Family Medicine and Primary Care, School of Clinical Medicine (Wan, C.K.H. Wong), Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; Aston Pharmacy School (I.C.K. Wong), Aston University, Birmingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip Hei Li
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy (Lai, Yan, Ye, Ma, Qin, X. Li, Wan, C.K.H. Wong, C.L. Cheung, I.C.K. Wong, Chan), Li Ka Shing Faculty of Medicine, The University of Hong Kong; Laboratory of Data Discovery for Health (Lai, Ma, Chui, X. Li, Wan, C.K.H. Wong, C.L. Cheung, I.C.K. Wong, Chan), Hong Kong Science and Technology Park; School of Nursing (Chui) and of Public Health (Chui) and Departments of Medicine (X. Li, P.H. Li, B.M.U. Cheung, Lau) and of Family Medicine and Primary Care, School of Clinical Medicine (Wan, C.K.H. Wong), Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; Aston Pharmacy School (I.C.K. Wong), Aston University, Birmingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernard Man Yung Cheung
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy (Lai, Yan, Ye, Ma, Qin, X. Li, Wan, C.K.H. Wong, C.L. Cheung, I.C.K. Wong, Chan), Li Ka Shing Faculty of Medicine, The University of Hong Kong; Laboratory of Data Discovery for Health (Lai, Ma, Chui, X. Li, Wan, C.K.H. Wong, C.L. Cheung, I.C.K. Wong, Chan), Hong Kong Science and Technology Park; School of Nursing (Chui) and of Public Health (Chui) and Departments of Medicine (X. Li, P.H. Li, B.M.U. Cheung, Lau) and of Family Medicine and Primary Care, School of Clinical Medicine (Wan, C.K.H. Wong), Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; Aston Pharmacy School (I.C.K. Wong), Aston University, Birmingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chak Sing Lau
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy (Lai, Yan, Ye, Ma, Qin, X. Li, Wan, C.K.H. Wong, C.L. Cheung, I.C.K. Wong, Chan), Li Ka Shing Faculty of Medicine, The University of Hong Kong; Laboratory of Data Discovery for Health (Lai, Ma, Chui, X. Li, Wan, C.K.H. Wong, C.L. Cheung, I.C.K. Wong, Chan), Hong Kong Science and Technology Park; School of Nursing (Chui) and of Public Health (Chui) and Departments of Medicine (X. Li, P.H. Li, B.M.U. Cheung, Lau) and of Family Medicine and Primary Care, School of Clinical Medicine (Wan, C.K.H. Wong), Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; Aston Pharmacy School (I.C.K. Wong), Aston University, Birmingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian Chi Kei Wong
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy (Lai, Yan, Ye, Ma, Qin, X. Li, Wan, C.K.H. Wong, C.L. Cheung, I.C.K. Wong, Chan), Li Ka Shing Faculty of Medicine, The University of Hong Kong; Laboratory of Data Discovery for Health (Lai, Ma, Chui, X. Li, Wan, C.K.H. Wong, C.L. Cheung, I.C.K. Wong, Chan), Hong Kong Science and Technology Park; School of Nursing (Chui) and of Public Health (Chui) and Departments of Medicine (X. Li, P.H. Li, B.M.U. Cheung, Lau) and of Family Medicine and Primary Care, School of Clinical Medicine (Wan, C.K.H. Wong), Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; Aston Pharmacy School (I.C.K. Wong), Aston University, Birmingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esther Wai Yin Chan
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy (Lai, Yan, Ye, Ma, Qin, X. Li, Wan, C.K.H. Wong, C.L. Cheung, I.C.K. Wong, Chan), Li Ka Shing Faculty of Medicine, The University of Hong Kong; Laboratory of Data Discovery for Health (Lai, Ma, Chui, X. Li, Wan, C.K.H. Wong, C.L. Cheung, I.C.K. Wong, Chan), Hong Kong Science and Technology Park; School of Nursing (Chui) and of Public Health (Chui) and Departments of Medicine (X. Li, P.H. Li, B.M.U. Cheung, Lau) and of Family Medicine and Primary Care, School of Clinical Medicine (Wan, C.K.H. Wong), Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China; Aston Pharmacy School (I.C.K. Wong), Aston University, Birmingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

This article has a correction. Please see:

  • Correction to “Booster vaccination with inactivated whole-virus or mRNA vaccines and COVID-19–related deaths among people with multimorbidity: a cohort study” - March 06, 2023

Abstract

Background: Multimorbidity is a prevalent risk factor for COVID-19–related complications and death. We sought to evaluate the association of homologous booster vaccination using BNT162b2 (Pfizer-BioNTech) or CoronaVac (Sinovac) with COVID-19–related deaths among people with multimorbidity during the initial Omicron wave of the COVID-19 pandemic.

Methods: Using routine clinical records from public health care facilities in Hong Kong, we conducted a territory-wide retrospective cohort study comparing people aged 18 years or older with 2 or more chronic conditions who received a homologous booster (third) dose with those who received only 2 doses, between Nov. 11, 2021, and Mar. 31, 2022. The primary outcome was death related to COVID-19.

Results: We included 120 724 BNT162b2 recipients (including 87 289 who received a booster), followed for a median of 34 (interquartile range [IQR] 20–63) days and 127 318 CoronaVac recipients (including 94 977 who received a booster), followed for a median of 38 (IQR 22–77) days. Among BNT162b2 recipients, booster-vaccinated people had fewer COVID-19–related deaths than those who received 2 doses (5 v. 34, incidence rate 1.3 v. 23.4 per million person-days, weighted incidence rate ratio [IRR] 0.05, 95% confidence interval [CI] 0.02–0.16). We observed similar results among recipients of CoronaVac booster vaccination compared with those who received only 2 doses (26 v. 88, incidence rate 5.3 v. 53.1 per million person-days, weighted IRR 0.08, 95% CI 0.05–0.12).

Interpretation: Among people with multimorbidity, booster vaccination with BNT162b2 or CoronaVac was associated with reductions of more than 90% in COVID-19–related mortality rates compared with only 2 doses. These results highlight the crucial role of booster vaccination for protecting vulnerable populations as the COVID-19 pandemic continues to evolve.

Compared with the general population, people living with multimorbidity are disproportionately burdened by the ongoing COVID-19 pandemic.1 Research shows a higher risk of SARS-CoV-2 infection2 and death related to COVID-19 among those with multimorbidity. 3,4 The global roll-out of SARS-CoV-2 vaccines, therefore, has rightfully prioritized people with underlying chronic conditions and multimorbidity.5 By late 2021, most eligible people had received at least 2 doses of the vaccines in many jurisdictions.6 Amid the emergence of new SARS-CoV-2 variants, however, people with multimorbidity may further benefit from booster vaccination, given an established tolerable safety profile of the vaccines in this particular population.7,8 Some studies have shown the effectiveness of certain vaccines against infection with new variants in the general population, such as the mRNA vaccines.9,10 However, the effectiveness of SARS-CoV-2 booster vaccination has not been well explored in people living with multimorbidity.

Despite an absence of evident local transmission of SARS-CoV-2 in Hong Kong from mid to late 2021,11 the city reported the world’s highest COVID-19–related mortality rate in proportion to population size amid the Omicron (BA.2) variant epidemic, which started in late December 2021.12 As of April 2022, more than 9000 deaths in Hong Kong were related to COVID-19, of a population of 7.5 million.11 Booster vaccination with 2 of the most widely used vaccines worldwide, namely the BNT162b2 mRNA vaccine (Fosun-BioNTech, equivalent to Pfizer-BioNTech outside China) and the CoronaVac inactivated whole-virus vaccine (Sinovac), has been available to eligible Hong Kong residents since Nov. 11, 2021. Older people, health care professionals and other priority groups were allowed to receive the booster vaccination first, before it was extended to all other adults on Jan. 1, 2022. More than 3 million people received the booster vaccination within the first 4 months of 2022.13

We sought to evaluate the effectiveness of a homologous booster dose of these vaccines in lowering the risk of COVID-19–related death among people with multimorbidity using a territory-wide electronic health record database in Hong Kong amid the Omicron wave of the pandemic.

Methods

Data sources

We identified SARS-CoV-2 vaccine recipients with multimorbidity from routine health care records provided by the Hospital Authority of Hong Kong, linked with population-based vaccination records at the Department of Health. The Hospital Authority serves as the sole provider of public inpatient services and is a major provider of outpatient services in Hong Kong, with a comprehensive electronic health record system for facilitation of clinical management. Further details are available in Appendix 1, available at www.cmaj.ca/lookup/doi/10.1503/cmaj.221068/tab-related-content.

Study design

We used a retrospective cohort study design to compare the risk of COVID-19–related deaths among adults with multimorbidity who had received a homologous booster dose against those who had received only 2 doses. We identified adults aged 18 years or older with diagnoses of 2 or more chronic conditions (of a widely adopted list of 30 conditions; Appendix 1, Supplementary Table 1) who had received a booster dose between Nov. 11, 2021 (the date of the official roll-out of booster vaccination), and Mar. 31, 2022, of the same SARS-CoV-2 vaccine they had received for the first 2 doses (BNT162b2 or CoronaVac).14,15 Both vaccines were made freely available to all residents of Hong Kong during the study period. Dozens of community vaccination centres that provided either vaccine were set up in geographically convenient public facilities for a wider reach to the community. Given its easier storage, the CoronaVac vaccine was made available in private clinics as well. The supply of both vaccines has been more than adequate since their roll-out in early 2021 (Feb. 23 for CoronaVac and Mar. 6 for BNT162b2). In general, Hong Kong residents were encouraged to receive the booster vaccine at least 180 days after their second dose. However, they were allowed to receive the booster vaccine from 90 days after the second dose for reasons such as having an underlying, immunocompromising condition. Residents could receive a booster dose less than 90 days after their second dose only with medical advice to do so, or in other exceptional cases.

We considered adults with multimorbidity (deceased or alive by the end of data availability) who had received their second vaccine dose at least 180 days before Mar. 31, 2022, but had not received the booster dose as the comparison cohort (i.e., the 2-dose group). We conducted random matching by age and sex so that a randomly chosen, booster-vaccinated individual was mapped to each 2-dose individual of the same age and sex; the date of booster vaccination served as the pseudo-index date for the 2-dose group. We adopted the 180-day interval as a criterion to ensure each age- and sex-matched 2-dose individual was assigned a pseudo-index date well after the date of their second dose. We built such a comparison cohort for each of the 2 vaccine types. We excluded people who had received heterologous vaccines and those who had received a second booster (fourth) dose from the main analysis. Hence, we included 2 study cohorts in the main analysis, namely the BNT162b2 cohort and the CoronaVac cohort.

We followed individuals from the index date (booster vaccination) or pseudo-index date until the outcome of interest, death related to COVID-19; we censored individuals upon death unrelated to COVID-19 or at the end of data availability (Mar. 31, 2022), whichever came first. We defined a death related to COVID-19 as one that was unrelated to injury or poisoning (International Classification of Diseases, 10th Revision code S00-T88), with a positive test result from a polymerase chain reaction test for SARS-CoV-2 within 28 days before death.16 We excluded people who received 2 doses but died before the pseudo-index date and people (2 doses or 3 doses) who developed multimorbidity only after the index (or pseudo-index) date.

We followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement checklist to guide transparent reporting of this study.17

Statistical analysis

We used propensity score–based, inverse probability of treatment, weighted Poisson regression, stratified by vaccine type (BNT162b2 v. CoronaVac) to estimate the weighted incidence rate ratio (IRR) of death related to COVID-19, comparing those who received the booster dose and those who received only 2 doses. Covariates for weighting included age, sex, time from second dose to index or pseudo-index date (d), presence of each of the 30 conditions used to define multimorbidity, as well as a range of chronic medications within 1 year before the index or pseudo-index date (see Appendix 1, Supplementary Table 2). Details regarding subgroup, secondary and sensitivity analyses are provided in the Appendix 1.

All statistical tests were 2-sided, and we considered p values less than 0.05 to be statistically significant. We conducted statistical analysis using R version 4.0.3 (www.R-project.org). We used the svyjskm package to generate a weighted Kaplan–Meier cumulative incidence plot. Two investigators (V.K.C.Y. and X.Y.) conducted the statistical analyses independently for quality assurance.

Ethics approval

As only anonymized secondary data analyses were involved, no informed consent was required. This research is approved by the Hospital Authority Central Institutional Review Board (CIRB-2021–005–4) and the Department of Health Ethics Committee (LM171/2021).

Results

We identified 3 290 178 people aged 18 years or older who had received at least 2 doses of SARS-CoV-2 vaccines as of Mar. 31, 2022, in the database, of which 519 191 had 2 or more of the 30 chronic conditions. After further removing ineligible participants by our exclusion criteria, we included 120 724 BNT162b2 recipients (including 87 289 who received a booster) and 127 318 CoronaVac recipients (including 94 977 who received a booster) in the analyses (Figure 1). The median follow-up time was 34 (interquartile range [IQR] 20–63) days for BNT162b2 recipients and 38 (IQR 22–77) days for CoronaVac recipients.

Figure 1:
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1:

Flow chart showing cohort selection.

Cohort characteristics

Table 1 and Table 2 show the BNT162b2 and CoronaVac cohort characteristics, respectively, before and after applying inverse probability of treatment weighting. People who received the booster dose were slightly older than those who received only 2 doses (64.9 v. 61.2 yr among BNT162b2 recipients; 67.9 v. 65.0 yr among CoronaVac recipients); the CoronaVac recipients were slightly older than the BNT162b2 recipients. The ratio of males to females was similar between groups, with slightly more males included. As of the index or pseudo-index date, about 20–30 more days had passed since the second dose vaccination among those who had received the booster than among those who received only 2 doses (Appendix 1, Supplementary Figure 1). For all 4 groups, the most prevalent chronic condition was hypertension (> 80%) followed by diabetes (> 60%), severe constipation (> 10%), chronic kidney disease (about 10%) and chronic pain (about 10%). More than 60% of participants had used calcium-channel blockers and about 60% had used lipid-lowering agents in the past year, followed by renin–angiotensin-system agents (about 50%) and antidiabetic medications (> 40%). After weighting, all characteristics had a standardized mean difference lower than 0.1, indicating a good balance between the booster and 2-dose groups for both vaccine cohorts.

View this table:
  • View inline
  • View popup
Table 1:

Cohort characteristics before and after inverse probability of treatment weighting for recipients of BNT162b2 vaccine (booster v. 2 doses)

View this table:
  • View inline
  • View popup
Table 2:

Cohort characteristics before and after inverse probability of treatment weighting for recipients of CoronaVac vaccine (booster v. 2 doses)

COVID-19–related deaths

The weighted cumulative incidence of COVID-19–related deaths across the follow-up period was higher among people who were vaccinated with 2 doses than among those who received a booster (Figure 2). CoronaVac recipients had a higher rate of mortality related to COVID-19 than BNT162b2 recipients. Appendix 1, Supplementary Figure 2 shows the unweighted cumulative incidence plots.

Figure 2:
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2:

Weighted cumulative incidence of COVID-19–related deaths after (A) BNT162b2 or (B) CoronaVac 2-dose or booster vaccination, with 95% confidence intervals (CIs) represented by the shaded area. The index date is operationalized as the date of booster vaccination or the matched pseudoindex date for those who received 2 doses of vaccine.

In total, 39 BNT162b2 recipients (including 5 who received a booster) and 114 CoronaVac recipients (including 26 who received a booster) died in relation to COVID-19, constituting an incidence rate of 0.7 per 100 000 person-days for BNT162b2 and and 1.7 per 100 000 person-days for CoronaVac. Weighted analysis estimated that a booster dose was associated with a reduced risk of COVID-19–related death among both BNT162b2 recipients (IRR 0.05, 95% confidence interval [CI] 0.02–0.16) and CoronaVac recipients (IRR 0.08, 95% CI 0.05–0.12) (Table 3).

View this table:
  • View inline
  • View popup
Table 3:

COVID-19–related deaths among people who received either 2 doses or booster vaccination, by vaccine type (BNT162b2 or CoronaVac)

Results were similar in a weighted subgroup analysis including only those aged 60 years or older (BNT162b2: IRR 0.06, 95% CI 0.02–0.16; CoronaVac: IRR 0.07, 95% CI 0.04–0.11) (Appendix 1, Supplementary Table 3). Interaction between booster vaccination and age was not significant for either vaccine in the multivariable Poisson regression analysis (BNT162b2: p = 0.9; CoronaVac: p = 0.7) (Appendix 1, Supplementary Table 4).

In an analysis combining the vaccine cohorts, 2 doses of BNT162b2 (IRR 0.49, 95% CI 0.31–0.78), booster vaccination with CoronaVac (IRR 0.03, 95% CI 0.01–0.08) and booster vaccination with BNT162b2 (IRR 0.07, 95% CI 0.04–0.11) were all associated with a lower risk of COVID-19–related death, compared with 2 doses of CoronaVac (Appendix 1, Supplementary Table 5). In an analysis of people who received a heterologous booster vaccine, no COVID-19–related deaths were recorded for those vaccinated with a BNT162b2-BNT162b2-CoronaVac series, and a reduced incidence of COVID-19–related deaths (IRR 0.02, 95% CI 0.00–0.06) was observed for those vaccinated with a CoronaVac-CoronaVac-BNT162b2 series, compared with 2 doses of CoronaVac (Appendix 1, Supplementary Table 6). In a weighted analysis similar to the primary analysis, the incidence of SARS-CoV-2 infection was also reduced with booster vaccination compared with 2-dose vaccination for both BNT162b2 (IRR 0.32, 95% CI 0.30–0.34) and CoronaVac (IRR 0.31, 95% CI 0.29–0.33) (Appendix 1, Supplementary Table 7).

Sensitivity analyses (including one in which each comorbidity was removed from the analysis; others in which the definition of COVID-19–related mortality required a positive polymerase chain reaction test for SARS-CoV-2 within 7, 14 or 28 days before death; one in which the index date was set 14 days after booster vaccination, with adjustment for potential competing risks from non-COVID-19–related deaths; and one with exclusion of people who developed COVID-19 before receiving their second vaccine dose showed consistent results with the main analysis (Appendix 1, Supplementary Tables 8–13).

Interpretation

We found a substantially reduced risk of COVID-19–related death in adults with multimorbidity who received a homologous booster dose of BNT162b2, an mRNA vaccine, or CoronaVac, an inactivated whole-virus vaccine. These results support the effectiveness of booster doses of vaccines of 2 different technological platforms in lowering mortality among those with multimorbidity amid the Omicron epidemic. Subgroup and sensitivity analyses showed similar results, supporting the robustness of our results. As the data on SARS-CoV-2 vaccination records used for this study was provided by the sole operator of vaccine roll-out in Hong Kong, with a unified recording system, and with linked clinical records provided by a territory-wide public health care provider, our data should be highly reliable and representative. Numerous previous high-impact pharmacovigilance studies have been generated from this database.8,18–25

Since the roll-out of the BNT162b2 vaccine, observational studies worldwide have consistently shown its effectiveness against infection, severe disease and death.9,10,26–29 More recent research on the booster dose has suggested substantial extra protection, in addition to that conferred by the first and second doses.27,28,30,31 An Israeli cohort study of people aged 50 years or older reported a 90% reduced hazard of COVID-19–related death associated with the booster dose of BNT162b2 compared with only 2 doses.28 In another cohort study of people aged 12 years or older, the reduced risk of COVID-19–related death was estimated at 81%.32 Our estimates of 95% reduced risk among those with BNT162b2 booster vaccination are possibly the highest risk reductions reported to date, plausibly because of the selection of a high-risk population with multimorbidity, although the adopted age was as low as 18 years. Another potential explanation for the high effectiveness observed in our cohort may be the waning of protection conferred by the first and second doses, given that the average number of days since the second dose well exceeded 180 days in both the weighted and unweighted cohorts; this extended period may have incurred a reduction of effectiveness by more than 20–30 percentage points, compared with 14 days after vaccination, according to a systematic review.33,34 Certain underlying conditions and old age in this population may also accelerate this waning protection.35

Given its much wider use in developing countries than in developed countries, CoronaVac’s effectiveness has not been investigated as extensively as BNT162b2 beyond clinical trials, wherein vaccination (including booster vaccination) generally showed good efficacy against infection, severe disease and death.29,36–39 In the cross-platform comparison, we showed that 2 doses of CoronaVac confer lower protection than 2 doses of BNT162b2, which agrees with the existing efficacy data, but 3 doses of either CoronaVac or BNT162b2 offered similar protection. Our large postmarketing cohort study thereby supports the effectiveness of a booster dose of CoronaVac against death related to COVID-19. Our findings should inform public health policies in countries that are considering the roll-out of booster doses of CoronaVac, especially for the aging population and in populations with a high prevalence of multimorbidity.

Limitations

Similar to other pharmacoepidemiologic studies, residual confounding may be present as randomization was not possible. Specifically, people with multimorbidity who chose to receive a booster dose earlier than others may be better educated, more health aware and more proactive in health-seeking behaviours. These people may therefore be better at self-care to minimize the risk of SARS-CoV-2 infection and, thus, the analysis may overestimate the effectiveness of the booster dose. Nevertheless, people in the comparison cohort had already received 2 doses (rather than including a mix of vaccinated and unvaccinated people), and such an overestimation, if any, should be minimal and may not affect the results substantially. The outcome of this study was operationalized as death with COVID-19 rather than death from COVID-19 because the adoption of the latter requires a thorough causality assessment for each outcome event, and it was not feasible, given the limited information in the database of electronic health records for such an assessment and the large number of events. The list of conditions for multimorbidity was far from exhaustive and may not be perfectly applicable to Hong Kong, but research has suggested that prevalence tends to converge at the inclusion of 12 or more prevalent conditions.40 Moreover, the sensitivity analysis showed no substantial effects of the change of multimorbidity components on the findings. Further research should investigate the impact of an increased burden of multimorbidity on vaccine effectiveness. Although we adjusted for the presence of chronic conditions, we did not determine or adjust for their severity. We did not have a sufficient sample size to evaluate the effectiveness of heterologous booster doses across platforms, which future research with adequate data should investigate.41 People who received 2 doses and who were discouraged from receiving a booster dose owing to a recent SARS-CoV-2 infection may have had increased immunity during the follow-up period. Nevertheless, this should bias the result only toward the null hypothesis and not affect our conclusion. The 2-dose vaccinated cohort may have been infected with SARS-CoV-2 and acquired a certain degree of immunity. We did not adjust for this possibility as we took an intention-to-treat perspective. We did not have data on the exact variant type for each individual in the database. Nevertheless, the observation period coincides with the Omicron BA.2 outbreak, which has been widely reported.12 We can reasonably generalize the findings and conclusions to Omicron BA.2. The population in Hong Kong is predominantly ethnic Chinese.42 Replication of the analysis should be conducted to test for generalizability to other populations.

Conclusion

The mass roll-out of the booster dose of SARS-CoV-2 vaccines in Hong Kong in November 2021 coincided with the arrival of the Omicron variant in late 2021. Our findings suggest that this timely, massive public health measure has plausibly played a pivotal role in lowering the mortality rate amid the epidemic, especially among people living with multimorbidity. They also highlight the potential benefit from booster vaccination, specifically in vulnerable populations living with multimorbidity, and support the recent focus on older people and those with chronic conditions for future booster doses of SARS-CoV-2 vaccines beyond the first booster.43

Acknowledgements

The authors thank the Hospital Authority and the Department of Health for the generous provision of data for this study, and Lisa Lam for language proofread of the manuscript.

Footnotes

  • Competing interests: Francisco Tsz Tsun Lai has been supported by the RGC Postdoctoral Fellowship under the Hong Kong Research Grants Council and has received research grants from the Food and Health Bureau of the Government of the Hong Kong Special Administrative Region. Tiantian Ma reports consulting fees from Laboratory of Data Discovery for Health. Celine Sze Ling Chui has received grants from the Food and Health Bureau of the Hong Kong Government, Hong Kong Research Grant Council, Hong Kong Innovation and Technology Commission, Pfizer, IQVIA and Amgen, as well as personal fees from PrimeVigilance. Xue Li has received research grants from the Research Grants Council Early Career Scheme, the Food and Health Bureau of the Government of the Hong Kong Special Administrative Region; research and educational grants from Janssen and Pfizer; internal funding from the University of Hong Kong; and consulting fees from Merck, Sharp and Dohme, and Pfizer. Eric Yuk Fai Wan has received research grants from the Food and Health Bureau of the Government of the Hong Kong Special Administrative Region, and the Hong Kong Research Grants Council. Carlos King Ho Wong reports funding from the EuroQoL Group Research Foundation, the Hong Kong Research Grants Council, and the Hong Kong Health and Medical Research Fund. Ian Chi Kei Wong receives research funding from Amgen, Bristol Myers Squibb, Pfizer, Janssen, Bayer, GSK, Novartis, the Hong Kong Research Grants Council, the Food and Health Bureau of the Government of the Hong Kong Special Administrative Region, the National Institute for Health Research in England, the European Commission and the National Health and Medical Research Council in Australia He also reports speaker fees from Janssen and Medice, and a role as an independent non-executive director of Jacobson Medical in Hong Kong. Esther Wai Yin Chan reports grants from the Research Grants Council of Hong Kong, the Research Fund Secretariat of the Food and Health Bureau of Hong Kong, the National Natural Science Fund of China, the Wellcome Trust, Bayer, Bristol Myers Squibb, Pfizer, Janssen, Amgen, Takeda and the Narcotics Division of the Security Bureau of Hong Kong. She also reports an honorarium from the Hong Kong Hospital Authority. All competing interests are outside the submitted work. No other competing interests were declared.

  • This article has been peer reviewed.

  • Contributors: Francisco Lai, Vincent Yan, Ian Wong and Esther Chan contributed to the conception of the work. All authors designed the study. Vincent Yan and Xuxiao Ye contributed to the acquisition and analysis of the data, and all authors interpreted the data. Francisco Lai drafted the manuscript. All of the authors revised the manuscript critically for important intellectual content, gave final approval of the version to be published and agreed to be accountable for all aspects of the work. Francisco Lai and Vincent Yan are co–first authors with equal contributions. Ian Wong and Esther Chan share senior authorship.

  • Funding: This work was funded by a research grant from the Food and Health Bureau of the Government of the Hong Kong Special Administrative Region, through the Health and Medical Research Fund Research on COVID-19 (COVID1903011). The funder was not involved in the study design, data collection, data analysis, data interpretation and writing of the report. Francisco Tsz Tsun Lai and Ian Chi Kei Wong are partially supported by the Laboratory of Data Discovery for Health, funded by the AIR@InnoHK and administered by the Innovation and Technology Commission.

  • Data sharing: Data will not be available for others as the data custodians have not given permission.

  • Accepted November 24, 2022.

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

References

  1. ↵
    1. Barnett K,
    2. Mercer SW,
    3. Norbury M,
    4. et al
    . Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012;380:37–43.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Chudasama YV,
    2. Gillies CL,
    3. Appiah K,
    4. et al
    . Multimorbidity and SARS-CoV-2 infection in UK Biobank. Diabetes Metab Syndr 2020;14:775–6.
    OpenUrlPubMed
  3. ↵
    1. Maddaloni E,
    2. D’Onofrio L,
    3. Alessandri F,
    4. et al
    . Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II). Cardiovasc Diabetol 2020;19:164.
    OpenUrl
  4. ↵
    1. Iaccarino G,
    2. Grassi G,
    3. Borghi C,
    4. et al
    . Age and multimorbidity predict death among COVID-19 patients. Hypertension 2020;76:366–72.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Powers AC,
    2. Aronoff DM,
    3. Eckel RH
    . COVID-19 vaccine prioritisation for type 1 and type 2 diabetes. Lancet Diabetes Endocrinol 2021;9:140–1.
    OpenUrl
  6. ↵
    1. Ritchie H,
    2. Mathieu E,
    3. Rodés-Guirao L,
    4. et al
    . Coronavirus pandemic (COVID-19). OurWorldInData.org. Available: https://ourworldindata.org/coronavirus (accessed 2022 Apr. 23).
  7. ↵
    1. Cao Y,
    2. Wang J,
    3. Jian F,
    4. et al
    . Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 2022;602:657–63.
    OpenUrl
  8. ↵
    1. Lai FTT,
    2. Huang L,
    3. Chui CSL,
    4. et al
    . Multimorbidity and adverse events of special interest associated with COVID-19 vaccines in Hong Kong. Nat Commun 2022;13:411.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Andrews N,
    2. Stowe J,
    3. Kirsebom F,
    4. et al
    . COVID-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med 2022;386:1532–46.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Sheikh A,
    2. Robertson C,
    3. Taylor B
    . BNT162b2 and ChAdOx1 nCoV-19 vaccine effectiveness against death from the Delta variant. N Engl J Med 2021;385:2195–7.
    OpenUrlCrossRefPubMed
  11. ↵
    WHO coronavirus (COVID-19) dashboard. Geneva: World Health Organization. Available: https://covid19.who.int/ (accessed 2022 Apr. 23).
  12. ↵
    1. Taylor L
    . Covid-19: Hong Kong reports world’s highest death rate as zero covid strategy fails. BMJ 2022;376:o707.
    OpenUrlFREE Full Text
  13. ↵
    Hong Kong vaccination dashboard. Hong Kong: Centre for Health Protection. Available: https://www.covidvaccine.gov.hk/en/dashboard/totalFirstDose (accessed 2022 Apr. 23).
  14. ↵
    1. Lai FTT,
    2. Beeler PE,
    3. Yip BHK,
    4. et al
    . Comparing multimorbidity patterns among discharged middle-aged and older inpatients between Hong Kong and Zurich: a hierarchical agglomerative clustering analysis of routine hospital records. original research. Front Med (Lausanne) 2021;8:651925.
    OpenUrl
  15. ↵
    1. Tonelli M,
    2. Wiebe N,
    3. Fortin M,
    4. et al
    . Methods for identifying 30 chronic conditions: application to administrative data. BMC Med Inform Decis Mak 2015;15:31.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Nyberg T,
    2. Ferguson NM,
    3. Nash SG,
    4. et al
    . Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet 2022;399:1303–12.
    OpenUrlPubMed
  17. ↵
    1. Skrivankova VW,
    2. Richmond RC,
    3. Woolf BAR,
    4. et al
    . Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration. BMJ 2021;375:n2233.
    OpenUrlFREE Full Text
  18. ↵
    1. Lai FTT,
    2. Chua GT,
    3. Chan EWW,
    4. et al
    . Adverse events of special interest following the use of BNT162b2 in adolescents: a population-based retrospective cohort study. Emerg Microbes Infect 2022;11:885–93.
    OpenUrl
    1. Lai FTT,
    2. Huang L,
    3. Peng K,
    4. et al
    . Post-COVID-19-vaccination adverse events and healthcare utilization among individuals with or without previous SARS-CoV-2 infection. J Intern Med 2022;291:864–9.
    OpenUrl
    1. Wan EYF,
    2. Chui CSL,
    3. Lai FTT,
    4. et al
    . Bell’s palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study. Lancet Infect Dis 2022;22:64–72.
    OpenUrlCrossRefPubMed
    1. Li X,
    2. Tong X,
    3. Yeung WWY,
    4. et al
    . Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong. Ann Rheum Dis 2022;81:564–8.
    OpenUrlAbstract/FREE Full Text
    1. Li X,
    2. Tong X,
    3. Wong ICK,
    4. et al
    . Lack of inflammatory bowel disease flare-up following two-dose BNT162b2 vaccine: a population-based cohort study. Gut 2022;71:2608–11.
    OpenUrlFREE Full Text
    1. Li X,
    2. Lai FTT,
    3. Chua GT,
    4. et al
    . Myocarditis following COVID-19 BNT162b2 vaccination among adolescents in Hong Kong. JAMA Pediatr 2022;176:612–4.
    OpenUrl
    1. Lai FTT,
    2. Li X,
    3. Peng K,
    4. et al
    . Carditis after COVID-19 vaccination with a messenger RNA vaccine and an inactivated virus vaccine. Ann Intern Med 2022;175:362–70.
    OpenUrlPubMed
  19. ↵
    1. Yan VKC,
    2. Wan EYF,
    3. Ye X,
    4. et al
    . Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case–control study. Emerg Microb Infect 2022;11:2304–14.
    OpenUrl
  20. ↵
    1. Lopez Bernal J,
    2. Andrews N,
    3. Gower C,
    4. et al
    . Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ 2021;373:n1088.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Bar-On YM,
    2. Goldberg Y,
    3. Mandel M,
    4. et al
    . Protection of BNT162b2 vaccine booster against COVID-19 in Israel. N Engl J Med 2021;385:1393–400.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Arbel R,
    2. Hammerman A,
    3. Sergienko R,
    4. et al
    . BNT162b2 vaccine booster and mortality due to COVID-19. N Engl J Med 2021;385:2413–20.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Arregocés-Castillo L,
    2. Fernández-Niño J,
    3. Rojas-Botero M,
    4. et al
    . Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort. Lancet 2022;3:e242–e252.
    OpenUrl
  24. ↵
    1. Magen O,
    2. Waxman JG,
    3. Makov-Assif M,
    4. et al
    . Fourth dose of BNT162b2 mRNA COVID-19 vaccine in a nationwide Setting. N Engl J Med 2022;386:1603–14.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Tartof SY,
    2. Slezak JM,
    3. Puzniak L,
    4. et al
    . Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: a retrospective cohort study. Lancet Reg Health Am 2022;9:100198.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Barda N,
    2. Dagan N,
    3. Cohen C,
    4. et al
    . Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet 2021;398:2093–2100.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Nordström P,
    2. Ballin M,
    3. Nordström A
    . Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. Lancet 2022;399:814–23.
    OpenUrlPubMed
  28. ↵
    1. Feikin DR,
    2. Higdon MM,
    3. Abu-Raddad LJ,
    4. et al
    . Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet 2022;399:924–44.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Andrews N,
    2. Tessier E,
    3. Stowe J,
    4. et al
    . Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK [preprint]. medRxiv 2021 Oct. 6. doi: 10.1101/2021.09.15.21263583
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Premikha M,
    2. Chiew CJ,
    3. Wei WE,
    4. et al
    . Comparative effectiveness of mRNA and inactivated whole virus vaccines against COVID-19 infection and severe disease in Singapore. Clin Infect Dis 2022;75:1442–5.
    OpenUrl
    1. Hitchings MDT,
    2. Ranzani OT,
    3. Torres MSS,
    4. et al
    . Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: a test-negative case-control study. Lancet Reg Health Am 2021;1:100025.
    OpenUrlPubMed
    1. Tanriover MD,
    2. Doganay HL,
    3. Akova M,
    4. et al
    . Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 2021;398:213–222.
    OpenUrlPubMed
  31. ↵
    1. Costa Clemens SA,
    2. Weckx L,
    3. Clemens R,
    4. et al
    . Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet 2022;399:521–9.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Fortin M,
    2. Stewart M,
    3. Poitras M-E,
    4. et al
    . A systematic review of prevalence studies on multimorbidity: toward a more uniform methodology. Ann Fam Med 2012; 10:142–51.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Gram MA,
    2. Nielsen J,
    3. Schelde AB,
    4. et al
    . Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: a nationwide population-based cohort study. PLoS Med 2021;18:e1003874.
    OpenUrlCrossRefPubMed
  34. ↵
    Thematic report: ethnic minorities. Hong Kong: 2016 Population By-census Office — Census and Statistics Department; 2017. Available: https://www.censtatd.gov.hk/en/data/stat_report/product/B1120100/att/B11201002016XXXXB0100.pdf (accessed 2022 Apr. 27).
  35. ↵
    1. Tanne JH
    . Covid-19: Pfizer asks US regulator to authorise fourth vaccine dose for over 65s. BMJ 2022;376:o711.
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 195 (4)
CMAJ
Vol. 195, Issue 4
30 Jan 2023
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Booster vaccination with inactivated whole-virus or mRNA vaccines and COVID-19–related deaths among people with multimorbidity: a cohort study
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Booster vaccination with inactivated whole-virus or mRNA vaccines and COVID-19–related deaths among people with multimorbidity: a cohort study
Francisco Tsz Tsun Lai, Vincent Ka Chun Yan, Xuxiao Ye, Tiantian Ma, Xiwen Qin, Celine Sze Ling Chui, Xue Li, Eric Yuk Fai Wan, Carlos King Ho Wong, Ching Lung Cheung, Philip Hei Li, Bernard Man Yung Cheung, Chak Sing Lau, Ian Chi Kei Wong, Esther Wai Yin Chan
CMAJ Jan 2023, 195 (4) E143-E152; DOI: 10.1503/cmaj.221068

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Booster vaccination with inactivated whole-virus or mRNA vaccines and COVID-19–related deaths among people with multimorbidity: a cohort study
Francisco Tsz Tsun Lai, Vincent Ka Chun Yan, Xuxiao Ye, Tiantian Ma, Xiwen Qin, Celine Sze Ling Chui, Xue Li, Eric Yuk Fai Wan, Carlos King Ho Wong, Ching Lung Cheung, Philip Hei Li, Bernard Man Yung Cheung, Chak Sing Lau, Ian Chi Kei Wong, Esther Wai Yin Chan
CMAJ Jan 2023, 195 (4) E143-E152; DOI: 10.1503/cmaj.221068
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Interpretation
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • Correction to “Booster vaccination with inactivated whole-virus or mRNA vaccines and COVID-19–related deaths among people with multimorbidity: a cohort study”
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Self-reported sleep disturbances among people who have had a stroke: a cross-sectional analysis
  • Risk of interpersonal violence during and after pregnancy among people with schizophrenia: a population-based cohort study
  • Perinatal outcomes of midwife-led care, stratified by medical risk: a retrospective cohort study from British Columbia (2008–2018)
Show more Research

Similar Articles

Collections

  • Topics
    • Infectious diseases: COVID-19
    • Multimorbidity
    • Public health
    • Vaccination

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire